OPRD1 Antibody

What is OPRD1 and why is it significant for research?

OPRD1 (Opioid Receptor Delta 1) is a G-protein coupled receptor that functions in cellular response to hypoxia and GPCR signaling pathways. The human version consists of 372 amino acid residues with a molecular mass of approximately 40.4 kilodaltons. It is primarily localized in cell membranes and is notably expressed in the kidney, hippocampus, cerebral cortex, cerebellum, and caudate regions . OPRD1 is particularly significant for research because, unlike other opioid receptor genes (OPRM1 and OPRK1), it is also expressed in metabolic tissues, especially the pancreas . Recent functional genetics research has revealed its crucial role in metabolic homeostasis, making it a potential therapeutic target for type 2 diabetes and related metabolic disorders .

How do OPRD1 antibodies differ from antibodies against other opioid receptors?

OPRD1 antibodies are specifically designed to target the delta opioid receptor, which has distinct structural and functional characteristics compared to mu (OPRM1) and kappa (OPRK1) opioid receptors. The specificity of these antibodies is achieved through careful selection of unique epitopes that do not cross-react with other opioid receptor subtypes. OPRD1 antibodies often target the extracellular N-terminal domain or specific phosphorylation sites (such as Ser363), providing researchers with tools to study receptor expression, localization, and post-translational modifications . Unlike antibodies against other opioid receptors, OPRD1 antibodies allow researchers to investigate the unique role of delta opioid receptors in both neural and metabolic tissues, offering insights into specialized signaling pathways and therapeutic potential .

What are the common alternative names for OPRD1 in scientific literature?

When reviewing scientific literature, researchers should be aware that OPRD1 is referenced under several alternative names and abbreviations. Common synonyms include OPRd (Opioid Receptor delta), DOP (Delta Opioid Receptor), DOR (Delta Opioid Receptor), and DOR1 . This nomenclature variation can complicate literature searches and database queries. When designing comprehensive literature reviews or bioinformatic analyses, researchers should incorporate all these alternative designations to ensure complete coverage of relevant research findings.

What are the most effective applications for OPRD1 antibodies in research?

OPRD1 antibodies demonstrate versatility across multiple experimental applications. Western Blot (WB) represents the most common and reliable application, allowing researchers to quantify OPRD1 expression levels and detect potential post-translational modifications . Immunohistochemistry (IHC) and Immunocytochemistry (ICC) enable visualization of receptor distribution in tissue sections and cultured cells, respectively. Immunofluorescence (IF) provides higher-resolution localization data, particularly useful for co-localization studies with other proteins. ELISA techniques offer quantitative measurement of OPRD1 in biological samples . For studying receptor dynamics in living cells, antibodies targeting extracellular epitopes (such as the N-terminal region) are particularly valuable as they can potentially detect the receptor without cell permeabilization . Flow cytometry (FACS) applications have also been developed for quantifying receptor expression across cell populations .

What methodological considerations should be addressed when using OPRD1 antibodies for Western Blotting?

When conducting Western Blot analysis with OPRD1 antibodies, several methodological considerations must be addressed to ensure robust and reproducible results:

• Sample preparation: Due to OPRD1's membrane localization, effective membrane protein extraction is critical. Use specialized membrane protein extraction buffers containing appropriate detergents (e.g., RIPA buffer with 0.1% SDS or 1% Triton X-100).

• Denaturation conditions: OPRD1, being a seven-transmembrane protein, may form aggregates during sample heating. Optimize denaturation temperature (typically 70°C for 10 minutes rather than boiling) to maintain epitope integrity.

• Gel percentage selection: The 40.4 kDa size of OPRD1 is optimally resolved on 10-12% polyacrylamide gels.

• Transfer conditions: Extended transfer times (90-120 minutes) at moderate voltage are recommended for efficient transfer of membrane proteins.

• Blocking solution optimization: BSA-based blocking solutions (3-5%) often yield better results than milk-based alternatives for membrane proteins.

• Antibody dilution: Start with manufacturer-recommended dilutions (typically 1:1000 for primary antibodies) and optimize based on signal-to-noise ratio.

• Controls: Include positive controls (tissues known to express OPRD1 such as brain extracts) and negative controls (tissues or cell lines with minimal OPRD1 expression).

• Post-translational modifications: Consider using phospho-specific antibodies (such as those targeting pSer363) when studying receptor regulation .

How can researchers optimize immunohistochemistry protocols for OPRD1 detection in different tissue types?

Optimizing immunohistochemistry protocols for OPRD1 detection requires tissue-specific adjustments:

• Fixation method: For neural tissues (hippocampus, cerebral cortex), 4% paraformaldehyde fixation for 24 hours preserves OPRD1 epitopes while maintaining tissue architecture. For metabolic tissues (pancreas), shorter fixation times (8-12 hours) may improve antibody penetration.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is generally effective for OPRD1 detection. For tissues with high endogenous protease activity (like pancreas), additional protease inhibitors in the buffer may be beneficial.

• Section thickness: 5-8 μm sections provide optimal resolution for cellular localization studies.

• Blocking parameters: Extended blocking (2 hours at room temperature) with 5-10% normal serum from the secondary antibody host species reduces background.

• Primary antibody incubation: Overnight incubation at 4°C with optimized antibody concentration improves specific binding and signal quality.

• Detection systems: For tissues with lower OPRD1 expression (like pancreatic islets), amplification systems such as tyramide signal amplification may enhance detection sensitivity.

• Counterstaining: Hematoxylin counterstaining at reduced intensity preserves visibility of DAB-based detection of OPRD1.

• Controls: Include both positive control tissues (cerebellum, caudate) and negative controls (primary antibody omission and pre-absorption with immunizing peptide) .

How does species reactivity impact OPRD1 antibody selection for cross-species studies?

Species reactivity is a critical consideration when selecting OPRD1 antibodies, particularly for comparative studies across different model organisms. The sequence homology of OPRD1 varies between species, resulting in differential antibody recognition. For instance, antibodies targeting the extracellular N-terminal domain (AA 2-18) may recognize mouse and rat OPRD1 but fail to detect human OPRD1 due to sequence divergence in this region .

When designing cross-species studies, researchers should:

• Verify the documented species reactivity for each antibody before purchase.

• Select antibodies targeting conserved epitopes when cross-species detection is required.

• Consider using multiple antibodies targeting different epitopes to validate findings across species.

• Perform preliminary validation experiments with positive control samples from each species of interest.

• Be aware that sequence conservation does not always translate to equivalent antibody affinity – titration experiments may be necessary for each species.

For researchers working with human samples alongside rodent models, it's essential to select antibodies with validated human reactivity or to use species-specific antibodies for each experimental model .

What are the advantages and limitations of targeting different OPRD1 epitopes?

The selection of target epitopes for OPRD1 antibodies presents distinct advantages and limitations:

N-Terminal (Extracellular) Epitopes (e.g., AA 2-18)

• Advantages: Can detect receptors in living cells; useful for studies of receptor internalization and trafficking; suitable for immunoprecipitation of native (non-denatured) receptors.

• Limitations: May have species-specific reactivity (e.g., mouse/rat but not human); potentially affected by N-terminal modifications or ligand binding .

Central Domain Epitopes (e.g., AA 81-180)

• Advantages: Often more conserved across species; less affected by receptor conformation changes.

• Limitations: In transmembrane regions, may require more stringent denaturation for access in fixed samples .

C-Terminal (Intracellular) Epitopes

• Advantages: Highly specific for Western blot applications; useful for detecting receptor-protein interactions at the intracellular domain.

• Limitations: Requires cell permeabilization for immunocytochemistry applications; may be affected by post-translational modifications or protein-protein interactions .

Phospho-Specific Epitopes (e.g., pSer363)

• Advantages: Allows detection of specific activation states of the receptor; enables studies of receptor regulation and signaling.

• Limitations: Signal depends on phosphorylation state, which may be labile during sample processing; requires careful validation with phosphatase controls .

Researchers should select epitopes based on their specific experimental questions and technical requirements.

What validation methods should be employed to confirm OPRD1 antibody specificity?

Rigorous validation of OPRD1 antibody specificity is essential for generating reliable research data. Comprehensive validation should include:

• Knockout/knockdown controls: Testing the antibody in tissues/cells where OPRD1 expression has been genetically eliminated (knockout) or reduced (knockdown). A specific antibody should show absent or reduced signal in these samples.

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide before application to samples. Specific binding should be blocked by the peptide, resulting in signal elimination.

• Multiple antibody approach: Using multiple antibodies targeting different epitopes of OPRD1. Concordant results across antibodies increase confidence in specificity.

• Cross-reactivity testing: Evaluating potential cross-reactivity with other opioid receptors (mu and kappa) and related GPCRs through overexpression systems.

• Western blot molecular weight verification: Confirming that the detected band corresponds to the expected molecular weight of OPRD1 (approximately 40.4 kDa), with consideration for post-translational modifications that may alter mobility.

• Correlation with mRNA expression: Comparing protein detection patterns with OPRD1 mRNA expression data from qPCR or in situ hybridization.

• Recombinant protein controls: Using purified recombinant OPRD1 as a positive control for antibody binding.

• Species-specificity confirmation: Validating reactivity claims by testing across samples from multiple species .

How does OPRD1 expression in pancreatic tissue influence experimental design for metabolic studies?

OPRD1 expression in pancreatic tissue presents unique considerations for experimental design in metabolic studies. Unlike other opioid receptors, OPRD1 is notably expressed in metabolic tissues, with particular significance in pancreatic islets and beta cells . This expression pattern influences experimental design in several key ways:

• Tissue sampling strategy: When isolating pancreatic tissue, researchers should employ protocols that preserve islet integrity and consider regional heterogeneity in OPRD1 expression across pancreatic compartments.

• Cell-type specific analysis: Given that OPRD1 expression in the pancreas appears concentrated in beta cells, single-cell isolation techniques or co-staining with beta cell markers (like insulin) should be incorporated into study designs.

• Pathological state considerations: OPRD1 expression decreases under type 2 diabetes conditions, necessitating experimental designs that account for disease state influence on receptor levels .

• Functional readouts: When studying OPRD1 in pancreatic tissue, insulin secretion assays become important functional readouts, as DOP inhibition enhances insulin secretion from beta cells .

• Pharmacological approach: Experimental designs should incorporate both agonists and antagonists of DOP to fully elucidate receptor function in metabolic contexts.

• Temporal considerations: Circadian factors may influence OPRD1 expression and function, as RNA-sequencing has identified circadian clock pathways regulated by DOP antagonism .

These considerations enable researchers to more effectively investigate OPRD1's role in metabolic homeostasis and its potential as a therapeutic target for metabolic disorders.

What is the significance of OPRD1 genetic variants for metabolic disease research?

Research into OPRD1 genetic variants has revealed significant implications for metabolic disease research. Functional genetics studies have identified a compelling relationship between OPRD1 variants and metabolic parameters:

Loss-of-Function Variants:

• Associated with higher adiposity (92% of carriers were overweight/obese versus 58% of non-carriers)

• Associated with lower hyperglycemia risk (15% in carriers versus 47% in non-carriers)

• Demonstrated a statistically significant effect on BMI (p=0.044 in RaDiO study; p=0.0028 in UK Biobank)

Gain-of-Function Variants:

• Associated with lower adiposity

• Associated with higher type 2 diabetes risk

• Mirror the metabolic effects observed in loss-of-function variants

This relationship is summarized in the following table derived from the research findings:

These findings suggest that OPRD1 function has opposing effects on adiposity and glycemic control, positioning it as a potential therapeutic target with nuanced metabolic effects. Researchers investigating metabolic diseases should consider OPRD1 genetic screening as part of comprehensive patient characterization and potentially for stratifying study populations .

How can researchers effectively study the relationship between OPRD1 function and insulin secretion?

To effectively study the relationship between OPRD1 function and insulin secretion, researchers should implement a comprehensive experimental approach:

• In vitro beta cell models:

  • Use established beta cell lines (e.g., INS-1, MIN6) with confirmed OPRD1 expression

  • Complement with primary isolated pancreatic islets from rodent models

  • Validate findings in human islets when available

• Receptor modulation strategies:

  • Pharmacological approach: Apply selective DOP antagonists (e.g., naltrindole) to inhibit receptor function

  • Genetic approach: Use CRISPR/Cas9 to generate OPRD1 knockout or knockdown models in beta cell lines

  • Overexpression studies: Introduce wild-type or variant OPRD1 to assess dose-dependent effects

• Insulin secretion assays:

  • Static incubation assays: Measure insulin secretion in response to glucose challenges with/without DOP modulation

  • Perifusion studies: Assess dynamic insulin secretion patterns over time

  • Include both basal and stimulated conditions to assess differential effects

• Molecular signaling analysis:

  • Investigate cAMP signaling pathways affected by OPRD1 modulation

  • Examine calcium dynamics in beta cells following receptor inhibition

  • Explore G-protein coupling specificity in pancreatic versus neural tissues

• RNA-sequencing approach:

  • Perform transcriptomic analysis following DOP antagonism to identify regulated pathways

  • Focus on nerve growth factor, circadian clock, and nuclear receptor pathways previously implicated

  • Validate key targets with qPCR and protein analysis

• In vivo verification:

  • Conduct glucose tolerance tests in animal models with pharmacological or genetic OPRD1 manipulation

  • Assess both acute and chronic effects of OPRD1 modulation on glucose homeostasis

  • Consider sex-specific differences in OPRD1 function

This multifaceted approach will provide comprehensive insights into how OPRD1 influences insulin secretion and glucose homeostasis, potentially revealing new therapeutic targets for metabolic disorders .

What are common troubleshooting approaches for non-specific binding in OPRD1 immunodetection?

Non-specific binding represents a significant challenge in OPRD1 immunodetection. When encountering this issue, researchers should implement the following troubleshooting strategies:

• Optimize blocking conditions:

  • Increase blocking solution concentration (5-10% normal serum or BSA)

  • Extend blocking duration (2-3 hours at room temperature)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • Consider alternative blocking agents (casein, commercial blocking buffers)

• Adjust antibody parameters:

  • Further dilute primary antibody (particularly important for polyclonal antibodies)

  • Reduce incubation temperature (4°C) and extend incubation time (overnight)

  • Add 0.1-0.5% non-ionic detergent (Tween-20) to antibody diluent

  • Pre-absorb polyclonal antibodies with tissue/cell lysate from OPRD1-negative samples

• Modify washing protocols:

  • Increase wash duration and number of washes (e.g., 5-6 washes of 10 minutes each)

  • Use higher salt concentration in wash buffers (150-300 mM NaCl)

  • Add 0.05-0.1% Tween-20 to wash buffers

• Implement additional controls:

  • Include isotype control antibodies at equivalent concentration

  • Conduct secondary-only controls to assess secondary antibody specificity

  • Perform peptide competition assays with graduated peptide concentrations

• Adjust detection parameters:

  • For Western blot: Reduce exposure time, use more stringent washing, consider alternative ECL substrates

  • For IHC/IF: Titrate chromogen/fluorophore development time, reduce secondary antibody concentration

• Sample-specific considerations:

  • For tissues with high endogenous biotin, use biotin-blocking steps before antibody application

  • For tissues with high endogenous peroxidase activity, implement more rigorous peroxidase quenching

  • For fixed tissues with excessive cross-linking, optimize antigen retrieval methods

How can post-translational modifications of OPRD1 be effectively studied using antibody-based approaches?

Studying post-translational modifications (PTMs) of OPRD1 requires specialized antibody-based approaches:

• Phosphorylation studies:

  • Utilize phospho-specific antibodies targeting key regulatory sites (e.g., pSer363)

  • Implement phosphatase inhibitors during sample preparation (sodium orthovanadate, sodium fluoride)

  • Include lambda phosphatase treatment as negative control

  • Combine with metabolic labeling using 32P for quantitative assessment

  • Consider Phos-tag SDS-PAGE for mobility shift detection of phosphorylated species

• Glycosylation analysis:

  • Use lectins in conjunction with OPRD1 antibodies for co-localization studies

  • Implement enzymatic deglycosylation (PNGase F, Endo H) followed by Western blot to assess mobility shifts

  • Compare binding efficiency of antibodies targeting extracellular versus intracellular epitopes

• Ubiquitination detection:

  • Employ co-immunoprecipitation with OPRD1 antibodies followed by ubiquitin detection

  • Include proteasome inhibitors during sample preparation to preserve ubiquitinated species

  • Apply tandem ubiquitin binding entities (TUBEs) for enrichment of ubiquitinated OPRD1

• SUMOylation assessment:

  • Conduct sequential immunoprecipitation with OPRD1 and SUMO antibodies

  • Utilize SUMO-specific proteases as controls

  • Implement protocols optimized to preserve this labile modification (e.g., inclusion of N-ethylmaleimide)

• Receptor internalization and trafficking:

  • Combine surface biotinylation with OPRD1 immunoprecipitation to track receptor movement

  • Utilize antibodies against extracellular epitopes for non-permeabilized immunofluorescence

  • Implement live-cell imaging with antibody fragments (Fab) to monitor real-time trafficking

• Analytical considerations:

  • Always include both modified and unmodified control samples

  • Consider enrichment strategies to detect low-abundance modified forms

  • Validate antibody-based findings with complementary approaches like mass spectrometry

What advanced experimental approaches can be used to study OPRD1 in complex tissue environments?

Investigating OPRD1 in complex tissue environments requires sophisticated experimental approaches:

• Multiplex immunofluorescence techniques:

  • Implement spectral unmixing for simultaneous detection of OPRD1 and multiple cell-type markers

  • Utilize tyramide signal amplification for detection of low-abundance OPRD1

  • Apply sequential immunostaining protocols to overcome antibody host limitations

  • Consider clearing techniques (CLARITY, iDISCO) for thick tissue specimens

• Single-cell analysis approaches:

  • Combine fluorescence-activated cell sorting with OPRD1 antibodies for isolation of receptor-expressing populations

  • Implement single-cell RNA-seq to correlate receptor expression with transcriptional signatures

  • Apply proximity ligation assay to detect OPRD1 protein interactions in situ with single-cell resolution

• Spatial transcriptomics integration:

  • Correlate OPRD1 protein distribution (by immunohistochemistry) with spatial transcriptomics data

  • Implement in situ hybridization for OPRD1 mRNA coupled with immunodetection of the protein

  • Validate protein-mRNA correlations across different tissue regions

• Ex vivo tissue models:

  • Utilize pancreatic slice cultures to maintain tissue architecture while enabling manipulation

  • Apply organoid models derived from metabolic tissues to study OPRD1 in a three-dimensional context

  • Implement microfluidic devices for controlled perfusion of OPRD1 modulators in tissue slices

• In vivo imaging approaches:

  • Develop OPRD1-targeted antibody fragments conjugated to near-infrared fluorophores

  • Apply intravital microscopy to study OPRD1 dynamics in living tissues

  • Consider PET imaging with radiolabeled antibodies or ligands for whole-body OPRD1 distribution

• Functional correlation strategies:

  • Combine OPRD1 immunodetection with functional readouts (e.g., calcium imaging, insulin secretion)

  • Implement optogenetic approaches in conjunction with OPRD1 antibody labeling

  • Correlate receptor expression patterns with electrophysiological recordings in neural tissues

These advanced approaches enable researchers to study OPRD1 within its native microenvironment, providing insights into its cell-type specific functions and interactions in both neural and metabolic tissues.

What emerging technologies might enhance OPRD1 antibody development and application?

Several emerging technologies hold promise for enhancing OPRD1 antibody development and applications:

• Single B-cell antibody discovery platforms:

  • Enable identification of highly specific monoclonal antibodies against complex OPRD1 epitopes

  • Facilitate development of conformational antibodies that recognize native receptor structure

  • Allow rapid screening of antibody candidates for specificity and affinity

• Nanobody and single-domain antibody approaches:

  • Develop smaller antibody fragments with enhanced tissue penetration

  • Create intrabodies capable of tracking OPRD1 in living cells

  • Engineer bispecific constructs targeting OPRD1 and its interaction partners simultaneously

• CRISPR epitope tagging:

  • Generate knock-in models with endogenous OPRD1 tagged for reliable detection

  • Enable visualization of OPRD1 dynamics without reliance on antibody specificity

  • Facilitate pull-down assays with standardized affinity tags

• Synthetic antibody libraries:

  • Design phage display libraries optimized for GPCR epitopes

  • Develop antibodies targeting specific conformational states of OPRD1

  • Create panels of antibodies covering the entire OPRD1 structure

• Advanced imaging applications:

  • Implement expansion microscopy for super-resolution imaging of OPRD1 in tissues

  • Apply DNA-PAINT techniques for multiplexed detection with single-molecule resolution

  • Develop live-cell nanoscopy approaches for tracking OPRD1 dynamics

• AI-enhanced antibody design:

  • Utilize computational approaches to predict optimal epitopes for antibody generation

  • Model antibody-antigen interactions to enhance specificity and reduce cross-reactivity

  • Implement machine learning for epitope selection based on sequence conservation across species

These technologies will likely transform our ability to detect, track, and manipulate OPRD1 in increasingly complex experimental systems, advancing both basic science and translational research .

How might OPRD1 antibodies contribute to therapeutic development for metabolic disorders?

OPRD1 antibodies have significant potential to contribute to therapeutic development for metabolic disorders through multiple avenues:

• Target validation and mechanistic understanding:

  • Enable precise localization of OPRD1 in metabolic tissues to confirm therapeutic relevance

  • Facilitate investigation of receptor regulation in diabetes pathophysiology

  • Allow correlation between receptor expression patterns and metabolic phenotypes

• Biomarker development:

  • Support development of diagnostic assays measuring OPRD1 levels or modifications in accessible samples

  • Enable patient stratification based on receptor expression patterns

  • Facilitate monitoring of therapeutic responses to OPRD1-targeting agents

• Antibody-based therapeutics:

  • Development of antagonistic antibodies targeting extracellular domains of OPRD1

  • Creation of bispecific antibodies linking OPRD1 to regulatory proteins

  • Engineering of antibody-drug conjugates for targeted delivery to OPRD1-expressing cells

• Drug discovery support:

  • Establishment of screening assays for OPRD1 modulators using antibody-based detection

  • Development of competitive binding assays to identify novel ligands

  • Creation of conformation-specific antibodies to screen for state-selective compounds

• Precision medicine applications:

  • Identification of OPRD1 variants with differential drug responses

  • Development of companion diagnostics for OPRD1-targeting therapeutics

  • Correlation of genetic findings with protein expression and function

• Combinatorial therapy approaches:

  • Investigation of OPRD1 interactions with other metabolic regulators

  • Development of multi-target approaches combining OPRD1 modulation with other mechanisms

  • Exploration of tissue-specific effects to maximize metabolic benefits while minimizing side effects

The discovery that DOP inhibition enhances insulin secretion from beta cells, coupled with the association between OPRD1 variants and metabolic parameters, positions OPRD1 antibodies as valuable tools in developing novel therapeutic strategies for type 2 diabetes and related disorders .